Biogen and Eisai expand existing collaboration agreement
Eisai and Biogen announced today the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta antibody. October 23, 2017